Page 118 - Binder2

Durable biologics would be manufactured in ways that
minimize immunogenic impurities—like non-native
glycosylation patterns or host cell proteins that trigger
immune recognition. That means moving beyond
traditional CHO cell expression systems to platforms like
plant-based expression, microbial fermentation, or cell-
free synthesis that produce cleaner, more tolerable
molecules.

They would also take advantage of tolerogenic
adjuvants—compounds specifically designed not to
amplify the immune response, but to reshape it. These
aren’t traditional vaccine adjuvants that supercharge
immunity. They’re the opposite: molecular instructors that
signal, “Stand down. This is safe.”

Think of them as immune context cues—co-delivered
with the biologic to help dendritic cells interpret the
therapy not as a danger signal, but as a normal part of the
environment. Compounds like rapamycin-loaded
nanoparticles, TGF-β mimetics, and mucosal
immunomodulators are already being studied for their
ability to trigger regulatory T cell induction, dampen
antigen-presenting cell activation, and steer the immune
response away from rejection and toward acceptance.

These aren’t hypothetical tools. They’re being built now—
in academic labs, in stealth biotech startups, in translational
immunology groups that understand what the current
system ignores: you can’t command the immune system
into cooperation. You have to teach it.

And that teaching doesn’t end with molecular co-signaling.
It extends to timing, frequency, and dose—the
choreography of exposure.

116